Subject to change.
Subject to change.
Sanam Rashidi, PharmD, leads the development and implementation of U.S. strategies for lung cancer and research at Roche. Over the past six years, she has focused on advancing precision oncology by supporting the approval of both novel companion diagnostic solutions and therapeutics that enable personalized treatment. Her work spans clinical and research applications to bring innovative technologies to pathology labs to improve patient care. Dr. Rashidi holds a PharmD from UC San Francisco.